Signatera™ CDx Approved by the FDA for Muscle-Invasive Bladder Cancer
Natera, Inc. has received FDA approval for Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer (MIBC) for use with atezolizumab (Tecentriq®) immunotherapy. This marks the first approval of a companion diagnostic in blood-based minimal residual disease (MRD) and signifies a major advancement in personalized cancer treatment.
AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC. This is the first companion diagnostic approval in the field of blood-based MRD. It is a significant milestone in the industry-wide shift toward personalized, MRD-guided cancer care, in